Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Medullary Thyroid Cancer
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of medullary thyroid cancer patients who decide to enroll in a clinical trial
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption.
The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of medullary thyroid cancer
- •Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- •No serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Exclusion Criteria
- •Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
- •Any serious and/or unstable pre-existing medical disorders
- •Patients who are currently receiving any other investigational drug.
Outcomes
Primary Outcomes
Number of medullary thyroid cancer patients who decide to enroll in a clinical trial
Time Frame: 3 months
Rate of medullary thyroid cancer patients who remain in clinical trial to trial completion
Time Frame: 12 months